Lightnews — Scholar-powered news

Conversation with Trinity Capital's Life Science Lead Rob Lake #2

December 24, 2025 at 4:47 PM

John Vandermosten

@vanjohn10.bsky.social

#ICYMI, here is the 2nd installment of a conversation with Trinity Capital's Rob Lake who explores post-COVID performance in the life sciences, acknowledges the patent cliff & reviews M&A trends.
$TRIN
youtu.be/be1JI6m7AsU

Conversation with Trinity Capitals Life Science Lead Rob Lake #1

December 22, 2025 at 4:47 PM

John Vandermosten

@vanjohn10.bsky.social

#ICYMI, we speak with Trinity Capital's Life Science Lead Rob Lake in part 1 of a two part series. We look at some of the ways private capital can be used to help developing companies achieve milestones and limit dilution.
$TRIN
www.youtube.com/watch?v=Dx0E...

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million | Athira Pharma

www.youtube.com

December 19, 2025 at 2:45 PM

John Vandermosten

@vanjohn10.bsky.social

Athira Pharma to acquire lasofoxifene in Ph3 development with funding participation by Ligand Pharma. $LGND has an agreement to receive milestones & tiered royalty of 6-10% on future next sales.
Drug treats ESR1-mutant breast cancer.
$ATHA
investors.athira.com/news-release...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing C...

investors.athira.com

December 18, 2025 at 10:45 PM

John Vandermosten

@vanjohn10.bsky.social

Ligand Partner Palvella Therapeutics granted FDA Fast Track designation for QTORIN Rapamycin.
$LGND $PVLA
ir.palvellatx.com/news-release...

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas - Tue, 12/16/2025 - 07:30

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN™ rapamycin for a...

ir.palvellatx.com

December 17, 2025 at 11:16 PM

John Vandermosten

@vanjohn10.bsky.social

A patient's degree of schizophrenia is often measured by the Positive and Negative Syndrome Scale (PANSS).
Reviva CEO Dr Bhat provides symptom examples.
#schizophrenia #biopharma #biotech
$RVPH
youtu.be/3zYbRsr4xZo

Positive and Negative Symptoms

Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

December 17, 2025 at 4:38 PM

John Vandermosten

@vanjohn10.bsky.social

Dyadic & Fermbox expand collaboration
*Animal-free proteins & enzymes in multiple markets
*Allows for new $DYAI & Fermbox products to be manufactured & commercialized
*Life sciences, food, nutrition & bioindustrial markets
finance.yahoo.com/news/dyadic-...

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineer...

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

December 17, 2025 at 4:06 PM

John Vandermosten

@vanjohn10.bsky.social

Protalix Bio & Secarna Pharma enter into collaboration & option agreement
*Novel antisense oligonucleotide therapies
*$PLX will identify targets in renal indications
*Secarna will contribute the OligoCreator AI platform
finance.yahoo.com/news/protali...

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases wi...

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

December 17, 2025 at 3:55 PM

John Vandermosten

@vanjohn10.bsky.social

GeoVax #CEO David Dodd provides his perspective on new approaches to #vaccine distribution in developing and remote regions.
#biotech #biotechnology #science

December 16, 2025 at 5:22 PM

John Vandermosten

@vanjohn10.bsky.social

Trinity Capital’s Rob Lake looks at private capital’s ability to stretch runway to achieve milestones while minimizing dilution
$TRIN
#LifeSciences #BiotechInnovation #BiotechFunding #MedTech #HealthTech #BioTechStartups #BioPharma #DrugDevelopment #ClinicalResearch #Therapeutics #PharmaInnovation

December 16, 2025 at 5:00 PM

John Vandermosten

@vanjohn10.bsky.social

Lexaria Bioscience $3.5mm raise
*2.66mm shares
*$1.315/sh
*2.66mm warrants @ $1.19
*Close expected today
$LEXX
finance.yahoo.com/news/lexaria...

KELOWNA, BC / ACCESS Newswire / December 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it h...

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

December 16, 2025 at 2:52 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA releases Kintara's REM001 CVR
*Releases 1.5mm $HURA shares to former Kintara shareholders
*10 patients
*Meets safety endpoint & signs of clinical efficacy
*With primary focus on IFx2.0, anti-VISTA & DOR inhibitor, next steps for REM001 unclear
finance.yahoo.com/news/tuhura-...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that...

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

December 16, 2025 at 2:38 PM

John Vandermosten

@vanjohn10.bsky.social

Dyadic partners with Opes Diagnostics to commercialize $DYAI's recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in life science, food & nutrition
*EU, Israel & Asia
finance.yahoo.com/news/dyadic-...

JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

December 15, 2025 at 1:30 PM

John Vandermosten

@vanjohn10.bsky.social

Radiopharm Theranostics reports 92% concordance between RAD101 & MRI as assessed by PET imaging of brain metastases
*Significant & selective tumor uptake
*Call @ 6 pm ET tonight
$RADX
finance.yahoo.com/news/radioph...

92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent b...

December 15, 2025 at 1:25 PM

John Vandermosten

@vanjohn10.bsky.social

Dr. Ann Childress, principal investigator on Cingulate's CTx-1301 trials shares other data reported from the study. Notably, & in contrast to the pediatric study, the adult study was mostly female.
$CING
youtu.be/Rl_co75JDB8

CTx 1301 Adult Data

TuHURA Biosciences Corporate Update Call

December 14, 2025 at 5:15 PM

John Vandermosten

@vanjohn10.bsky.social

#CEO David Dodd looks at the possible futures for GeoVax and the company’s focus during a surge in M&A activity.
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #GeneTherapy #HeadAndNeckCancer #SolidTumor #CancerResearch #Oncology #InnovativeMedicine #Biotech #TargetedTherapy

December 13, 2025 at 7:37 PM

John Vandermosten

@vanjohn10.bsky.social

Trinity Capital’s Rob Lake looks at private capital’s ability to stretch runway to achieve milestones while minimizing dilution
$TRIN
#LifeSciences #BiotechInnovation #BiotechFunding #MedTech #HealthTech #BioTechStartups #BioPharma #DrugDevelopment #ClinicalResearch #Therapeutics #PharmaInnovation

December 13, 2025 at 7:34 PM

John Vandermosten

@vanjohn10.bsky.social

GeoVax' #CEO David A. Dodd looks at the Modified Vaccinia Ankara (MVA) platform & how $GOVX is adapting it to be used in developing and developed regions alike.
#biotech #biotechnology #science #GeoVax #Gedeptin #CancerTherapy #GeneTherapy #HeadAndNeckCancer #SolidTumor #CancerResearch #Oncology

December 12, 2025 at 8:54 PM

John Vandermosten

@vanjohn10.bsky.social

Trinity Capital’s Rob Lake looks at some of the ways his platform recycles capital as investments achieve milestones or are acquired.
$TRIN
#LifeSciences #BiotechInnovation #BiotechFunding #MedTech #HealthTech #BioTechStartups #BioPharma #DrugDevelopment #ClinicalResearch #Therapeutics

December 11, 2025 at 6:45 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA Bio provides an update on its portfolio:
*Ph3 IFx2.0 ongoing, 4Q26 enrollment completion
*VISTA for AML
*Presentations @ ASH
*$16mm financing
*Webcast replay: edge.prnewswire.com/c/link/?t=0&...

Thursday, December 11, 2025 at 8:30 AM Eastern Standard Time.

edge.prnewswire.com

December 11, 2025 at 3:10 PM

John Vandermosten

@vanjohn10.bsky.social

Dr. Ann Childress, principal investigator on Cingulate's CTx-1301 trials explains the importance identifying the optimal dose for ADHD patients.
$CING
youtu.be/K5rPEw7OJLI

Forced Dose Titration Study

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

December 10, 2025 at 2:49 PM

John Vandermosten

@vanjohn10.bsky.social

As a follow up to the USPTO patent issuance, here is a brief clip of GeoVax' #CEO David Dodd looking at some of the evidence for Gedeptin's use in other solid tumors beyond head and neck cancer.
youtu.be/u8S6oslLCOw

December 10, 2025 at 2:39 PM

John Vandermosten

@vanjohn10.bsky.social

TuHURA announces $15.6mm capital raise
*9.5mm shares @ $1.65
*9.5mm warrants @ $1.95
*Issuances to occur in 3 tranches over the next 3 months
*Proceeds will pay off note & fund pipeline development
$HURA
finance.yahoo.com/news/tuhura-...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that...